Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
3.210
-0.060 (-1.83%)
At close: Sep 11, 2026, 4:00 PM EDT
3.150
-0.060 (-1.87%)
After-hours: Sep 11, 2026, 7:42 PM EDT
Pyxis Oncology Revenue
Pyxis Oncology had revenue of $11.04M in the twelve months ending June 30, 2026, up 291.42% year-over-year. In the year 2025, Pyxis Oncology had annual revenue of $13.86M, down -14.17%.
Revenue (ttm)
$11.04M
Revenue Growth
+291.42%
P/S Ratio
24.26
Revenue / Employee
$197,107
Employees
56
Market Cap
267.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.86M | -2.29M | -14.17% |
| Dec 31, 2024 | 16.15M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 65.05M |
| Bicycle Therapeutics | 61.21M |
| Foghorn Therapeutics | 36.74M |
| AC Immune | 21.67M |
| ProQR Therapeutics | 21.05M |
| Lineage Cell Therapeutics | 13.08M |
| Fate Therapeutics | 6.49M |
PYXS News
- 3 days ago - Pyxis Oncology price target raised to $8 from $7 at H.C. Wainwright - TheFly
- 4 days ago - Pyxis Oncology price target raised to $19 from $12 at Wells Fargo - TheFly
- 4 days ago - Pyxis Oncology announces updated results from micvotabart pelidotin study - TheFly
- 4 days ago - Pyxis Oncology Transcript: Study update - Transcripts
- 4 days ago - Pyxis Oncology Press release: Study update - Filings
- 4 days ago - Pyxis Oncology Slides: Study update - Filings
- 4 days ago - Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) - GlobeNewsWire
- 5 days ago - Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) - GlobeNewsWire